KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCash from Discontinued OperationsCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Change in Account Payables (2016 - 2025)

TherapeuticsMD (TXMD) has disclosed Change in Account Payables for 16 consecutive years, with -$87000.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Change in Account Payables fell 195.6% year-over-year to -$87000.0, compared with a TTM value of $29000.0 through Sep 2025, up 106.28%, and an annual FY2024 reading of $231000.0, up 110.82% over the prior year.
  • Change in Account Payables was -$87000.0 for Q3 2025 at TherapeuticsMD, down from $174000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $5.0 million in Q3 2021 and bottomed at -$10.8 million in Q1 2021.
  • Average Change in Account Payables over 5 years is -$219578.9, with a median of $4000.0 recorded in 2024.
  • The sharpest move saw Change in Account Payables plummeted 946.84% in 2023, then skyrocketed 4250.0% in 2025.
  • Year by year, Change in Account Payables stood at $414000.0 in 2021, then plummeted by 80.92% to $79000.0 in 2022, then tumbled by 946.84% to -$669000.0 in 2023, then soared by 103.59% to $24000.0 in 2024, then plummeted by 462.5% to -$87000.0 in 2025.
  • Business Quant data shows Change in Account Payables for TXMD at -$87000.0 in Q3 2025, $174000.0 in Q2 2025, and -$82000.0 in Q1 2025.